PharVision Advisers’s Quanex NX Stock Holding History

PharVision Advisers’s Portfolio NX Stock Details NX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-25,253	Closed	-$388K	–	478
2025 Q4	$388K	Buy	25,253 +2,711	+12%	+$38.3K	0.2%	138
2025 Q3	$321K	Buy	+22,542	New	+$422K	0.18%	188

Other funds holding NX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

DRZID

DePrince Race & Zollo Inc (DRZ) Winter Park, Florida $5.96B AUM 38.5% 1-Year Est. Return

SFM

Systematic Financial Management Teaneck, New Jersey $5.02B AUM 66.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PharVision Advisers's NX Position: Q1 2026 in Review

PharVision Advisers sold out of Quanex (NX) in Q1 2026, closing a stake of 25,253 shares — an estimated $388K sold.

PharVision Advisers first reported a position in NX in Q3 2025 and held it in 2 quarters. The position peaked at $388K in Q4 2025. 191 funds tracked by Wall St. Rank hold NX as of Q1 2026.

PharVision Advisers reported no remaining Quanex position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 25,253 Quanex shares in Q1 2026, an estimated $388K.
PharVision Advisers first reported a position in Quanex in Q3 2025 and held it in 2 quarters.
PharVision Advisers's Quanex position peaked at $388K in Q4 2025.
191 funds tracked by Wall St. Rank held Quanex as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.